Translation
Notice: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

June 30, 2026

To whom it may concern:

Company name: KOA SHOJI HOLDINGS CO., LTD. (Code No. 9273, TSE Prime)
Name of representative: Toshiyuki SHUTO, President and Representative Director
Inquiries: Teruyuki TANAKA, Director in charge of New Business Development and Corporate Planning (TEL. +81-45-594-9820)

Notice Concerning Completion of KOA ISEI's Zao Factory 2

KOA SHOJI HOLDINGS CO., LTD. (the "Company") hereby announces that KOA ISEI Co., Ltd. (Head office: Yamagata City, Yamagata Prefecture; President and Representative Director: Toshihiro HIRONO; hereinafter "KOA ISEI"), a consolidated subsidiary of the Company, has completed construction of Zao Factory 2, which had been under development within the Zao Factory site.

With the construction of Zao Factory 2, the production capacity for pre-filled syringe formulations will reach approximately 17 million units per year in total, combined with Zao Factory 1. KOA ISEI will work to achieve an early start of factory operations and to further establish and enhance systems for increased production, with the aim of ensuring a stable supply of its primary products, for which demand from medical institutions is high. Through these efforts, KOA ISEI will continue to pursue its mission of "contributing to the stable supply of generics to build a world that leaves no one who needs medicine behind."

Facility Overview

Name	KOA ISEI Co., Ltd. Zao Factory 2
Location	2-1-7 Matsugaoka, Zao, Yamagata-shi, Yamagata-ken (within the Zao Factory site)
Features	Low-mix, high-volume production (syringe formulations)
Structure	Two-story fire-resistant steel-frame building with ALC panels
Building area	2,793.10 m^2
Total floor area	3,419.27 m^2
Filling equipment	High-volume syringe production line
Production capacity	Syringe formulations: 12 million units/year
Preparation tank capacity	120L (maximum)
Water equipment	5t (WFI), 4t (UF)
Products manufactured	Highly pharmacologically active injectable drugs / Pre-filled syringe formulations
Investment amount	¥6,800 million
Scheduled start of operations	July 2027

Exterior view of the factory



Inspection and packaging room



Future Outlook

This factory will have no impact on the Company's financial results for the fiscal year ending June 2026. The Company will make timely disclosures regarding the impact on financial results for fiscal years thereafter as appropriate.

As KOA ISEI approaches its 70th anniversary, it has set its vision for 2030 to evolve from “a generic drug manufacturer focused on injectable drugs” to “Japan’s top manufacturer of distinctive generic injectables,” and will continue to advance the enhancement of its production capacity and the establishment of a stable supply structure.